ADAMS Public Documents collection at *http://www.nrc.gov/reading-rm/adams.html.* To begin the search, select ''ADAMS Public Documents'' and then select ''*Begin Web-based ADAMS Search.''* For problems with ADAMS, please contact the NRC's Public Document Room (PDR) reference staff at 1–800–397–4209, 301–415–4737, or by email to *pdr.resource@nrc.gov.* The ADAMS accession number for each document referenced (if it available in ADAMS) is provided the first time that a document is referenced. The draft environmental impact statement (EIS) is available in ADAMS under accession Nos. ML15103A012 and ML15103A025, respectively.

- NRC's PDR: You may examine and purchase copies of public documents at the NRC's PDR, Room O1–F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852.
- Project Web site: The draft EIS can be accessed online at the Bell Bend COL specific Web page at: *http://www.nrc.gov/reactors/new-reactors/col/bell-bend.html.*

B. Submitting Comments

Please include Docket ID NRC–2008–0603 in the subject line of your comment submission.

The NRC cautions you not to include identifying or contact information that you do not want to be publicly disclosed in your comment submission. The NRC posts all comment submissions at *http://www.regulations.gov* as well as entering the comment submissions into ADAMS. The NRC does not routinely edit comment submissions to remove identifying or contact information.

If you are requesting or aggregating comments from other persons for submission to the NRC, then you should inform those persons not to include identifying or contact information that they do not want to be publicly disclosed in their comment submission. Your request should state that the NRC does not routinely edit comment submissions to remove such information before making the comment submissions available to the public or entering the comment submissions into ADAMS.

II. Background

The NRC is issuing for public comment NUREG–2179, ''Draft Environmental Impact Statement for the Combined License (COL) for the Bell Bend Nuclear Power Plant.'' The PPL submitted an application for the COL to construct and operate one new nuclear power plant at its BBNPP site, located in Luzerne County, Pennsylvania. The application was submitted by letter dated October 10, 2008, pursuant to part 52 of Title 10 of the *Code of Federal Regulations* (CFR). A notice of receipt and availability of the application including the environmental report was published in the **Federal Register** on November 13, 2008 (73 FR 67214). A notice of acceptance for docketing of the COL application was published in the **Federal Register** on December 29, 2008 (73 FR 79519). A notice of intent to prepare a draft EIS and to conduct scoping was published in the **Federal Register** on January 6, 2009 (74 FR 470). On March 30, 2012, PPL submitted a revised environmental report (Part 3 of the COL application), in accordance with 10 CFR 51.45 and 51.50, to provide detailed information regarding the revised site layout that was developed in order to avoid wetland impacts by relocating the power block footprint and other plant components. A notice of intent to conduct a supplemental scoping process on the revised site layout was published in the **Federal Register** on June 15, 2012 (77 FR 36012).

The draft EIS also supports the USACE's review and was prepared in accordance with the National Environmental Policy Act of 1969, as amended. The draft EIS also supports the USACE's review of the Department of the Army permit application from PPL (CENAB–OP–RPA–2008–01401). The USACE's Public Interest Review will be part of its Record of Decision and is not addressed in the draft EIS. As part of the USACE public comment process, the USACE will publish a notice (in the **Federal Register**) within 30 days of the publication of the draft EIS to solicit comments from the public regarding PPL's Department of the Army permit application for proposed work at the BBNPP site.

II. Request for Comment and Public Meetings

The NRC is requesting public comments on the draft EIS. The NRC and USACE staff will conduct two public meetings to present an overview of the draft EIS and to accept public comments on both the document and the associated Department of the Army permit application on Thursday, June 4, 2015, at Bloomsburg University, Monty's Building Upper Campus, 400 East Second Street, Bloomsburg, Pennsylvania 17815. The first meeting will convene at 3:00 p.m. and will continue until 5:30 p.m., as necessary. The second meeting will convene at 7:30 p.m., with a repeat of the overview portions of the first meeting, and will continue until 10:00 p.m., as necessary. For additional information regarding the meetings, see the NRC's Public Meeting Schedule Web site at *https://meetings.nrc.gov/pmns/mtg.* The agenda will be posted no later than 10 days prior to the meetings.

Dated at Rockville, Maryland, this 14th day of April 2015.

For the Nuclear Regulatory Commission.

Mark Delligatti,

Deputy Director, Division of New Reactor Licensing, Office of New Reactors.

[FR Doc. 2015–09274 Filed 4–20–15; 8:45 am]

BILLING CODE 7590–01–P

POSTAL REGULATORY COMMISSION

[Docket No. CP2015–59; Order No. 2442]

New Postal Product

AGENCY: Postal Regulatory Commission.

ACTION: Notice.

SUMMARY: The Commission is noticing a recent Postal Service filing concerning an addition of Global Reseller Expedited Package Contracts 1 to the competitive product list. This notice informs the public of the filing, invites public comment, and takes other administrative steps.

DATES: *Comments are due:* April 22, 2015.

ADDRESSES: Submit comments electronically via the Commission's Filing Online system at *http://www.prc.gov.* Those who cannot submit comments electronically should contact the person identified in the **FOR FURTHER INFORMATION CONTACT** section by telephone for advice on filing alternatives.

FOR FURTHER INFORMATION CONTACT: David A. Trissell, General Counsel, at 202–789–6820.

SUPPLEMENTARY INFORMATION:

Table of Contents

I. Introduction

On April 13, 2015, the Postal Service filed notice that it has entered into an additional Global Reseller Expedited Package Contracts 1 (GREP 1) negotiated service agreement (Agreement).[1]

To support its Notice, the Postal Service filed a copy of the Agreement, a copy of the Governors' Decision authorizing the product, a certification

[1] Notice of United States Postal Service of Filing a Functionally Equivalent Global Reseller Expedited Package 1 Negotiated Service Agreement and Application for Non-Public Treatment of Materials Filed Under Seal, April 13, 2015 (Notice).

of compliance with 39 U.S.C. 3633(a), and an application for non-public treatment of certain materials. It also filed supporting financial workpapers.

II. Notice of Commission Action

The Commission establishes Docket No. CP2015–59 for consideration of matters raised by the Notice.

The Commission invites comments on whether the Postal Service's filing is consistent with 39 U.S.C. 3632, 3633, or 3642, 39 CFR part 3015, and 39 CFR part 3020, subpart B. Comments are due no later than April 22, 2015. The public portions of the filing can be accessed via the Commission's Web site (*http://www.prc.gov*).

The Commission appoints Curtis E. Kidd to serve as Public Representative in this docket.

III. Ordering Paragraphs

It is ordered:

1. The Commission establishes Docket No. CP2015–59 for consideration of the matters raised by the Postal Service's Notice.

2. Pursuant to 39 U.S.C. 505, Curtis E. Kidd is appointed to serve as an officer of the Commission to represent the interests of the general public in this proceeding (Public Representative).

3. Comments are due no later than April 22, 2015.

4. The Secretary shall arrange for publication of this order in the **Federal Register**.

By the Commission.

Shoshana M. Grove,

Secretary.

[FR Doc. 2015–09031 Filed 4–20–15; 8:45 am]

BILLING CODE 7710–FW–P

REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION

[BAC 416404]

Annual Public Meeting; Reagan-Udall Foundation for the Food and Drug Administration

ACTION: Notice of annual meeting.

SUMMARY: The Reagan-Udall Foundation for the Food and Drug Administration (FDA), which was created by Title VI of the Food and Drug Administration Amendments Act of 2007, is announcing its annual public meeting. The purpose of this meeting is to provide an opportunity for the Foundation to engage with its stakeholders and receive public input on its efforts. The meeting will include an organizational update, project updates, panel discussion, and open Q & A.

DATES: The public meeting will be held on May 15, 2015, from 10 a.m. until 12 noon. Registration to attend the meeting and requests for oral presentation must be received by May 8, 2015. See the **SUPPLEMENTARY INFORMATION** section for information on how to register for the meeting.

ADDRESSES: The public meeting will be held The Pew Charitable Trusts Conference Center, 901 E St. NW., Washington, DC 20004. Entrance for the meeting is located on 9th St. NW., between F St. NW. and E St. NW.

FOR FURTHER INFORMATION CONTACT: Jane Reese-Coulbourne, Reagan-Udall Foundation for the FDA, 202–828–1205, *Meetings@ReaganUdall.org.*

SUPPLEMENTARY INFORMATION:

I. Background

The Reagan-Udall Foundation for the FDA (the Foundation) is an independent 501(c)(3) not-for-profit organization created by Congress to advance the mission of FDA to modernize medical, veterinary, food, food ingredient, and cosmetic product development; accelerate innovation; and enhance product safety. With the ultimate goal of improving public health, the Foundation provides a unique opportunity for different sectors (FDA, patient groups, academia, other government entities, and industry) to work together in a transparent way to create exciting new research projects to advance regulatory science.

The Foundation acts as a neutral third party to establish novel, scientific collaborations. Much like any other independently developed information, FDA evaluates the scientific information from these collaborations to determine how Reagan-Udall Foundation projects can help the Agency to fulfill its mission.

The Foundation's programmatic efforts are designed to improve the existing scientific tools (methods) used to evaluate products as well as foster the development of innovative tools and approaches. This is exemplified in the Foundation's projects including: The Innovation in Medical Evidence Development and Surveillance Program, which develops and evaluates methods for using observational electronic health care data for postmarket evidence generation, including postmarket safety surveillance; the PredicTox Project, which applies systems biology to develop mechanistic models to predict adverse events; and the Critical Path to Tuberculosis Drug Regimens Project, which looks at novel approaches to development and review of tuberculosis combination therapies. Additionally, the Foundation is establishing regulatory science fellowships as part of its broader education efforts aimed at building capacity in regulatory science.

II. Meeting Attendance and Participation

A. Registration

If you wish to attend the meeting, visit: *http://goo.gl/GX6ysw.* Please register for the meeting by May 8, 2015. Seating may be limited, so early registration is recommended. Registration is free and will be on a first-come, first-served basis. Onsite registration on the day of the meeting will be based on space availability.

B. Requests for Oral Comments

Interested persons may present comments at the public meeting. Comments will be scheduled to begin approximate at 11:40 a.m. Time allotted for comments may be limited to 3 minutes, dependent on number of requests received. Those desiring to make oral comments should notify Jane Reese-Coulbourne (see **FOR FURTHER INFORMATION CONTACT**) by May 8, 2015. Please include a brief statement of the general nature of the comments they wish to present along with your name, address, telephone number, and email.

The agenda for the public meeting will be posted on the event registration page: *http://goo.gl/GX6ysw* and the Reagan-Udall Web site: *http://goo.gl/aSVymH.*

C. Written Comments

Interested persons may submit either electronic or written comments to the Foundation at any time to *Comments@ReaganUdall.org,* or by mail to the Reagan-Udall Foundation for the FDA, 1025 Connecticut Ave. NW., Suite 1000, Washington, DC 20036. Please include your name, address, telephone number, and email when making comments.

III. Post-Meeting Materials

The Foundation plans to make meeting materials and meeting recording available to the public after the meeting. Once available, these materials will be posted at *http://goo.gl/aSVymH.*

Dated: April 15, 2015.

Jane Reese-Coulbourne,

Executive Director, Reagan-Udall Foundation for the FDA.

[FR Doc. 2015–09072 Filed 4–20–15; 8:45 am]

BILLING CODE 4164–04–P